lundi 1 septembre 2014

About drugs and why usual PC myths are counterproductive for patients

http://www.forbes.com/sites/theapothecary/2014/08/16/are-patents-leading-to-drugs-that-cure-the-wrong-patients/

http://faculty.chicagobooth.edu/eric.budish/research/BRW-Fixed-Patents-and-Cancer-R&D.pdf

http://www.amazon.com/gp/product/handle-buy-box/ref=dp_start-bbf_1_glance

Present problems with giant trials:
""These results highlight some of the challenges that may occur during the development of novel therapuetics that are directed toward the inflammatory cascade," they wrote. "In particular, inflammation acts along many complex and redundant pathways that may attenuate the utility of blocking highly specific targets."
Califf said the study also raises larger questions about problems with cardiovascular trials.
"You have to study tens of thousands of people at the cost of hundreds of millions of dollars before you even know if a treatment has promise," Califf said. "So we've got to figure out less expensive ways to do clinical trials. There are no shortcuts.""

Aucun commentaire:

 
Paperblog